IC
Immuno Cancer Biotherapeutics, Inc.
SEC filingBiotechnology · Canton, SD
Amount raised$75Ksold at filing
Total offeringNot stated
Investors in the raise3count reported to the SEC
FiledOct 15, 2026first sale Oct 9, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
James RoblExecutive Officer, Director
Stephen CollinsDirector
Executive officers, directors and promoters as listed on the Form D.